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The new‐user design has been widely used in pharmaco-
epidemiology.1,2 By following patients from the initiation of a treat-
ment, the new‐user design has several advantages over designs that
begin follow‐up on prevalent users. The new‐user design allows study
of the full time course of outcome risk after treatment initiation, with
representation of early and late events.1,3,4 It also ensures appropriate
temporal ordering of baseline confounders, exposures, and outcomes,
avoiding adjustment for intermediate variables that may have been
affected by treatment.1 Coupled with an active‐comparator design,5
new‐user approaches can mitigate the potential for immortal time‐bias6
and confounding by indication.7 The active comparator new‐user
design helps to articulate clearly a causal question about the benefits
and harms of starting a particular intervention in a more real‐world
setting.8 These theoretical and conceptual advantages have led to the
recommendation that such designs should be a default approach for
comparative effectiveness research studies.2,9,10
The new‐user design is a special case of the treatment decision
design,11 which begins follow‐up at the times when treatment
decisions are made (Figure 1). Framing the research question and anal-
ysis in this way connects estimates to treatment decisions, providing
information that is directly relevant to clinicians and patients. In the
analysis, researchers often present an observational analog to the
“intention‐to‐treat analysis,” in which patients are analyzed by their
initial treatment (or assigned treatment) group, regardless of treatment
changes and non‐adherence that occur during follow‐up. The use of the
language from randomized controlled trials suggests that, under the
assumption of no uncontrolled confounding, these adjusted estimates
are similar to what one would obtain in parallel group randomized con-
trolled trial conducted in the same population.
However, when treatment groups are inferred from the treatment
actually started by patients, we are implicitly conducting our analysisamong the “treatment compliers,” those patients who will follow the
treatment decision made during their encounter with the clinician
(Figure 1). Non‐adherence to initial treatment decisions has been
termed “primary non‐adherence” or “primary non‐compliance,”12,13
and has been found to be substantial in several studies.13-15 Comparing
prescription orders and filled claims using data linking electronic pre-
scribing records and pharmacy claims, primary non‐adherence ranged
between 23% and 55% for new medications intended for chronic use
among a large cohort of adult patients,13 and 15% and 17% for antidi-
abetics and antihypertensives, respectively.16,17 Using data from inte-
grated health care delivery systems, primary non‐adherence ranged
between 5% and 13% for newly initiated oral medications for hyperten-
sion, diabetes, and/or hyperlipidemia.18 The higher rates of primary
non‐adherence in the first citation might be attributable to patients
obtaining prescriptions outside of the context of their insurance (eg,
paying out of pocket), which would have appeared as primary non‐
adherence as no pharmacy claim would have been generated. Multiple
factors have been associated with primary non‐adherence, including
patient age, physician specialty, prescription copayments, prescription
of brand‐name drugs, medication class, and delivery route of
prescriptions.13,14
Non‐adherence to treatment has been extensively studied.
Undoubtedly, non‐adherence can occur throughout the course of a
treatment. Methods exist to estimate effects of treatment under full
compliance and perfect adherence, including Robins' generalized
methods.19,20 However, discussion of correction methods in the litera-
ture has typically focused on secondary non‐adherence, which occurs
later in the course of treatment relative to primary non‐adherence
(Figure 1). To our knowledge, primary non‐adherence to initial treat-
ment decisions has not been discussed as a methodological challenge
in comparative effectiveness research, although several studies have
examined ways to correct estimation of medication adherence when
it is an outcome of interest.21-23
KEY POINTS
• Primary non‐adherence to initial treatment decisions is
substantial but remains underappreciated in the
literature.
• Typical implementations of the common new‐user
design may not yield the desired effect estimate in the
presence of primary non‐adherence.
• Discussion of primary non‐adherence will help
epidemiologists understand the population under study
and to whom study results apply.
• Having a precise definition of the study population of
interest a priori will help to minimize selection bias or
sampling bias.In the presence of primary non‐adherence, conditioning on
starting treatment (eg, filling a prescription) changes the study sample
from one that has been prescribed a treatment to the selected group
of patients who were both prescribed treatment and were initially
adherent to that treatment. This sample may be systematically differ-
ent from the desired target population, which is (usually) individuals
who were prescribed treatment. Although we are often interested in
the effect of the decision to start a patient on treatment, we can often
only identify the patients who adhered to the decision with the new‐
user design when inferring treatment groups from the treatment
actually started by patients.
Consequently, by conditioning on initiating treatment, the new‐
user design yields an estimate of an average treatment effect in the
population of primary compliers (Figure 1). While we are interested
in the effect of the treatment decision, E[Yz = 1 − Yz = 0], where Z
denotes the assigned treatment and Yz denotes the counterfactual
outcome of interest, we would be able to estimate this effect if we
have treatment decision and factors contributing to such decision
measured. However, conditioning on primary adherence as implicitly
done with the standard implementation of a new‐user design, the
estimate changes to the effect of the treatment decision among
adherers (who collect an initial prescription), E[Yz = 1 − Yz = 0|A = 1]
where A indicates whether the patient filled the initial prescription.
The interpretation of such effect estimates is complicated by 2 poten-
tial biases: sampling bias and selection bias. These 2 biases pose
threats to different aspects of study validity despite the similarity it
may seem at first glance.
Primary non‐adherence could impair external validity in a specific
target population via sampling bias.24,25 When new use is an eligibility
criterion to identify the study sample and the propensity of primary
adherence is affected by certain patient characteristics, the resulting
study sample of primary compliers is not a random sample of the target
population of interest. Imagine a target population that consists of
80% of males and 20% females who were prescribed a treatment,
and all female patients initially adhered whereas only 50% of male
patients initiated. When we identify the study sample by conditioning
on initiating treatment with the new‐user design, the male to female
ratio in the study sample would be 2:1 instead of 4:1 in the target
population. When the treatment effect is heterogeneous by gender,
sampling bias occurs, where the estimate in such a study sample may
not generalize to the target population.
Primary non‐adherence could also impair internal validity via
selection bias, similar to secondary non‐adherence.26 This could be
viewed as a missing data problem as we only have information suchas prescription fill data on adherers. Restricting to patients with
complete data (as implicitly done by a new‐user design) yields
estimates in a selected subgroup of patients. It is common that factors
such as socioeconomic status cause both primary adherence and
outcomes. For example, if patients face high out‐of‐pocket costs for
a therapy, new users of that therapy with prescription fill data may
consist of patients of higher socioeconomic status who are less
price sensitive. In such settings, conditioning on primary adherence
(and restricting to those having prescription fill data) opens a back‐
door path from the treatment decision to the outcome through
socioeconomic status, creating selection bias in estimates of the effect
of the treatment decision (Figure 2).26
The type of bias, sampling bias or selection bias or both, that pri-
mary non‐adherence could cause depends on the target population
of interest and missing data. There has been a lack of clarity in the
literature as to the distinction between sampling bias due to a lack of
generalizability (external validity) and selection bias due to missing data
(internal validity).24 This point is clarified by specifying a target popula-
tion a priori.25 Specifically, once a target population is well defined and
eligibility criteria are used to identify the study sample, then patients
excluded from a study sample due to ineligibility cannot affect internal
validity and do not cause selection bias as it is generally construed.
However, care must be taken to make inferences to the target popula-
tion also defined by such exclusions, and a sampling bias may be
present if results are generalized to other target populations. Of
course, eligible patients removed from the study sample due to missingFIGURE 1 Study population by source of
anchoring point. The choice of anchoring point
determines the treatment effect being
estimated. In the presence of primary non‐
adherence, studying a sample of treatment
compliers yields a corrupted observational
intention‐to‐treat effect. This effect is
corrupted (differs) from one we would get
from studying the prescribed treatment group
FIGURE 2 Restricting to a level of a common effect (primary
adherence) of treatment decision, factors, and a cause of outcome
creates bias of the treatment decision and outcome relationship by
opening a back‐door path from the treatment decision to the outcome
through these factors such as socioeconomic status (SES)data may affect internal validity because their removal might cause a
selection bias. Alternatively, one can alter the target population to
exclude such people, and thereby trade sampling and selection biases.
In doing so, one should be guided by a scientific rationale.
Fortunately, the increasing availability of electronic health record
and e‐prescribing data creates an opportunity to study the problem
of primary non‐adherence, specifically for prescriptions intended for
chronic‐use. Primary non‐adherence for medications meant to be used
sporadically should be treated differently and is beyond our scope.
Characteristics of the overall sample prescribed the medication and
the complier sample can be reported.13,18 If substantial differences
were observed, using assumed models of the primary non‐adherence
mechanisms, results from the complier sample could be generalized
to the target population using, for example, inverse‐probability
weighting when all relevant factors contributing to primary non‐adher-
ence are measured.24 Furthermore, the order date of the prescription
by physicians can serve as a more meaningful index date, approximat-
ing that of the randomization date origin in randomized controlled
trials. Such an approach could also potentially address the problem of
missing exposure data caused by low‐cost generics27 or free medica-
tion samples.28 Primary non‐adherence also exists in trials when indi-
viduals assigned treatment do not take the treatment. Including the
primary non‐adherers in observational studies, thus, brings us closer
to trials when patients are analyzed by their initial assigned treatment
group. Augmenting the prescription fill data with treatment decisions
as evidenced in the electronic health data or e‐prescribing data, we
would be able to study the predictors of primary non‐adherence and
better understand the population we are studying and to whom our
results apply.
One limitation in the perspective that we have described herein
arises when one considers the cause of primary non‐adherence. Our
discussion thus far has assumed that primary non‐adherence is
preventable, eg, patients declining treatment because of economic
reasons. It is of interest to include such patients who are price‐
sensitive in the study population because we are interested in the
effect of treatment among patients starting treatment and these
patients are potential users when economic factors are removed.However, some primary non‐adherence may not be preventable, eg,
patients declining treatment because of religious or cultural belief.
Clearly, patients whowould never accept treatment should be excluded
from the study population. The effect of treatment in such patients
would not be estimable and would be of little clinical or policy
relevance. To avoid including patients with non‐preventable primary
non‐adherence in the study population, researchers should take steps
to exclude these patients a priori, eg, by requiring that patients have
some use of the health care system during a baseline period.
In summary, primary non‐adherence to initial treatment decisions
is substantial among patients newly prescribed medications but
remains underappreciated in the literature relative to secondary non‐
adherence, which occurs later in the course of treatment. Discussion
of primary non‐adherence will help epidemiologists understand the
population under study and to whom study results apply. In particular,
having a precise definition of the study population of interest a priori
will help minimize unnecessary biases.
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